Zydus Cadila has received the final approval from the US FDA to market memantine hydrochloride tablets USP, 5 mg and 10 mg. The drug is used for the treatment of moderate to severe dementia of the Alzheimer's type and will be produced at the group’s formulations manufacturing facility at Moraiya, in Ahmedabad.
The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.